REFERENCES
  1. Jefferson JW, Pradko JF, Muir KT. Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations. Clin Ther 2005;27:1685-1695.
  2. Benowitz NL, Zhu AZ, Tyndale RF, Dempsey D. Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state. Pharmacogenet Genom 2013;23:135-141.
  3. Sridar C, Kenaan C, Hollenberg PF. Inhibition of bupropion metabolism by selegiline: mechanism-based inactivation of human CYP2B6 and characterization of glutathione and peptide adducts. Drug Metab Dispos 2012;40:2256-2266.
  4. Daviss WB, Perel JM, Birmaher B, Rudolph GR, Melhem I, Axelson DA,et al . Steady-state clinical pharmacokinetics of bupropion extended-release in youths. J Am Acad Child Psy 2006;45:1503-1509.
  5. Nirogi R, Palacharla RC, Mohammed AR, Manoharan A, Ponnamaneni RK, Bhyrapuneni G. Evaluation of metabolism dependent inhibition of CYP2B6 mediated bupropion hydroxylation in human liver microsomes by monoamine oxidase inhibitors and prediction of potential as perpetrators of drug interaction. Chem-Biol Interact 2015;230:9-20.
  6. Kirchheiner J, Klein C, Meineke I, Sasse J, Zanger UM, Mürdter TE,et al . Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 2003;13:619-626.
  7. Zanger U, Klein K, Blievernicht T J, Hofmann MH, Schwab M. Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics 2007;8:743-759.
  8. Hesse LM, Venkatakrishnan K, Court MH, Moltke LL, Duan SX, Shader RI,et al . CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 2000;28:1176-1183.
  9. Stäuble CK, Lampert ML, Mikoteit T, Hatzinger M, Hersberger KE, Schwabedissen HEMZ.  Nonresponse to high-dose bupropion for depression in a patient carrying CYP2B6*6 and CYP2C19*17 variants: a case report.Pharmacogenomics 2020 ;21(16):1145-1150.
  10. Tomaz PR, Santos JR, Issa JS, Abe TO, Gaya PV, Krieger JE, et al . CYP2B6 rs2279343 polymorphism is associated with smoking cessation success in bupropion therapy. European J Clin Pharmacol 2015;71:1-7.
  11. Høiseth G, Haslemo T, Uthus LH, Molden E. Effect of CYP2B6*6 on steady-state serum concentrations of bupropion and hydroxybupropion in psychiatric patients: a study based on therapeutic drug monitoring data. Ther Drug Monit 2015;37:589-593.
  12. Qin WJ, Zhang W, Liu ZQ, Chen XP, Tan ZR, Hu DL, et al . Rapid clinical induction of bupropion hydroxylation by metamizole in healthy Chinese men. Brit J Clin Pharmaco 2012;74:999–1004.
  13. Zhu AZ, Cox LS, Nollen N, Faseru B, Okuyemi KS, Ahluwalia JS, et al . CYP2B6 and bupropion’s smoking-cessation pharmacology: the role of hydroxybupropion. Clin Pharmacol Ther 2012;92:771-777.
  14. Ma H, Zhang WP, Yang XY, Zhang YX, Wei SJ, Zhang H, et al . Effects of genetic polymorphisms of CYP2B6 on the pharmacokinetics of bupropion and hydroxybupropion in healthy Chinese subjects. Med Sci Monit 2018, 24:2158-2163.
  15. Mohamed EF, Mohamed MM, Trueman S, Feng T, Enejosa J, Fisniku O, et al. Characterization of the effect of upadacitinib on the pharmacokinetics of bupropion, a sensitive cytochrome p450 2b6 probe substrate. Clinical Pharmacology in Drug Development 2020, Doi: 10.1002/cpdd.844.
  16. Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, et al. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 2000;28:1222-1230.
  17. Lainesse A, Hussain S, Monif T, Reyar S, Tippabhotla SK, Madan A,et al . Bioequivalence studies of tacrolimus capsule under fasting and fed conditions in healthy male and female subjects. Arzneimittel-Forsch 2008;58:242-247.
  18. Coles R, Kharasch ED. Stereoselective analysis of bupropion and hydroxybupropion in human plasma and urine by LC/MS/MS. J Chromatogr B 2007;857:67-75.
  19. Tao WA, And FCG, Cooks RG. Mass Spectrometric Quantitation of Chiral Drugs by the Kinetic Method. Anal Chem 2001;73:1692-1698.
  20. Parekh JM, Sutariya DK, Vaghela RN, Sanyal M, Yadav M, Shrivastav PS. Sensitive, selective and rapid determination of bupropion and its major active metabolite, hydroxybupropion, in human plasma by LC-MS/MS: application to a bioequivalence study in healthy Indian subjects. Biomed Chromatogr 2012;26:314-326.
  21. Denooz R, Mercerolle M, Lachâtre G, Charlier C. Ultra-performance liquid chromatography- tandem mass spectrometry method for the determination of bupropion and its main metabolites in human whole blood. J Anal Toxicol 2010;34:280-286.
  22. Hiratsuka M, Hinai Y, Konno Y, Nozawa H, Konno S, Mizugaki M. Three Novel Single Nucleotide Polymorphisms (SNPs) of the CYP2B6 Gene in Japanese Individuals. Drug Metab Pharmacok 2011;26:544-7.
  23. Murphy J, Wang SS, Stieltjes H, Wajs E, Devineni D. Effect of food on the pharmacokinetics of canagliflozin/metformin (150/1,000 mg) immediate-release fixed-dose combination tablet in healthy participants. Int J Clin Pharm Th 2015;53:256-264.
  24. Alkhalidi BA, Tamimi JJ, Salem II, Ibrahim H, Sallam AA. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers. Clin Ther 2008;30:1831-1843.
  25. Chen C, Bujanover S, Kareht S, Rapoport AM. Differential pharmacokinetics of diclofenac potassium for oral solution vs. immediate-release tablets from a randomized trial: effect of fed and fasting conditions. J Head Face Pain 2015;55:265-275.
  26. Filipe A, Almeida S, Spínola ACF, Neves R, Trabelsi F, Torns A,et al . Bioequivalence study of two enteric-coated formulations of pantoprazole in healthy volunteers under fed conditions. Arzneimittel-Forsch 2008;58:451-456.
  27. Devineni D, Manitpisitkul P, Murphy J, Stieltjes H, Ariyawansa J, Prospero NAD, et al . Effect of food on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, and assessment of dose proportionality in healthy participants. Clin Pharm Drug Dev 2015;4:279–286.
  28. Ilic K, Hawke RL, Thirumaran RK, Schuetz EG, Hull JH, Kashuba AD,et al . The influence of sex, ethnicity, and CYP2B6 genotype on bupropion metabolism as an index of hepatic CYP2B6 activity in humans. Drug Metab Dispos 2013;41:575-581.